Published in Am J Psychiatry on October 01, 2003
Epidemiology of Alzheimer disease. Nat Rev Neurol (2011) 4.13
Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol (2014) 1.86
Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities. Neural Plast (2012) 1.00
Trisomy-21 gene dosage over-expression of miRNAs results in the haploinsufficiency of specific target proteins. RNA Biol (2010) 0.98
Neurological phenotypes for Down syndrome across the life span. Prog Brain Res (2012) 0.98
Differential effects of trisomy on brain shape and volume in related aneuploid mouse models. Am J Med Genet A (2007) 0.93
Genetics studies indicate that neural induction and early neuronal maturation are disturbed in autism. Front Cell Neurosci (2014) 0.89
Visuo-spatial ability in individuals with Down syndrome: is it really a strength? Res Dev Disabil (2014) 0.89
Measuring fractional anisotropy of the corpus callosum using diffusion tensor imaging: mid-sagittal versus axial imaging planes. Korean J Radiol (2008) 0.84
Dementia in Down's syndrome: an MRI comparison with Alzheimer's disease in the general population. J Neurodev Disord (2013) 0.83
From abnormal hippocampal synaptic plasticity in down syndrome mouse models to cognitive disability in down syndrome. Neural Plast (2012) 0.82
Florbetapir PET, FDG PET, and MRI in Down syndrome individuals with and without Alzheimer's dementia. Alzheimers Dement (2015) 0.81
Complexity of force output during static exercise in individuals with Down syndrome. J Appl Physiol (1985) (2009) 0.81
Accurate and Fully Automatic Hippocampus Segmentation Using Subject-Specific 3D Optimal Local Maps Into a Hybrid Active Contour Model. IEEE J Transl Eng Health Med (2014) 0.79
Age effects on cortical thickness in young Down's syndrome subjects: a cross-sectional gender study. Neuroradiology (2015) 0.78
Neuroimaging of schizophrenia: structural abnormalities and pathophysiological implications. Neuropsychiatr Dis Treat (2005) 0.78
The Down syndrome brain in the presence and absence of fibrillar β-amyloidosis. Neurobiol Aging (2017) 0.78
Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease. Croat Med J (2014) 0.77
Developing an Informant Questionnaire for Cognitive Abilities in Down Syndrome: The Cognitive Scale for Down Syndrome (CS-DS). PLoS One (2016) 0.76
Measurement of the corpus callosum using magnetic resonance imaging in the north of iran. Iran J Radiol (2011) 0.75
The LonDownS adult cognitive assessment to study cognitive abilities and decline in Down syndrome. Wellcome Open Res (2016) 0.75
Infant Temperament: An Evaluation of Children with Down Syndrome. J Reprod Infant Psychol (2006) 0.75
The GABAergic Hypothesis for Cognitive Disabilities in Down Syndrome. Front Cell Neurosci (2017) 0.75
Structural brain alterations of Down's syndrome in early childhood evaluation by DTI and volumetric analyses. Eur Radiol (2016) 0.75
Large recurrent microdeletions associated with schizophrenia. Nature (2008) 20.25
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet (2008) 10.52
Common variants conferring risk of schizophrenia. Nature (2009) 10.37
Mild cognitive impairment. Lancet (2006) 10.21
Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med (2012) 10.16
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol (2010) 8.74
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA (2009) 7.29
GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron (2007) 6.88
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol (2010) 6.55
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A (2003) 6.46
CSF markers for incipient Alzheimer's disease. Lancet Neurol (2003) 6.12
Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 5.55
A genome-wide investigation of SNPs and CNVs in schizophrenia. PLoS Genet (2009) 5.01
Classifying brain states and determining the discriminating activation patterns: Support Vector Machine on functional MRI data. Neuroimage (2005) 4.83
Disruption of the neurexin 1 gene is associated with schizophrenia. Hum Mol Genet (2008) 4.78
Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N Engl J Med (2009) 4.45
CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain (2006) 3.95
Longitudinal stability of MRI for mapping brain change using tensor-based morphometry. Neuroimage (2006) 3.85
Identifying depression in primary care: a comparison of different methods in a prospective cohort study. BMJ (2003) 3.78
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol (2009) 3.65
Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol (2012) 3.48
Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. Am J Psychiatry (2002) 3.20
Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci U S A (2005) 3.02
Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging (2003) 2.96
Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Neuroimage (2009) 2.80
Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data. Int J Neuropsychopharmacol (2010) 2.74
The diagnosis and treatment of generalized anxiety disorder. Dtsch Arztebl Int (2013) 2.73
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry (2008) 2.64
Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One (2010) 2.57
3D characterization of brain atrophy in Alzheimer's disease and mild cognitive impairment using tensor-based morphometry. Neuroimage (2008) 2.40
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry (2007) 2.40
Focal decline of cortical thickness in Alzheimer's disease identified by computational neuroanatomy. Cereb Cortex (2004) 2.36
Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: an ADNI study of 515 subjects. Neuroimage (2009) 2.28
Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging (2010) 2.27
Use of neuroanatomical pattern classification to identify subjects in at-risk mental states of psychosis and predict disease transition. Arch Gen Psychiatry (2009) 2.17
Hippocampal changes in patients with a first episode of major depression. Am J Psychiatry (2002) 2.15
Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry (2009) 2.09
Automated cortical thickness measurements from MRI can accurately separate Alzheimer's patients from normal elderly controls. Neurobiol Aging (2006) 2.09
Association of the brain-derived neurotrophic factor Val66Met polymorphism with reduced hippocampal volumes in major depression. Arch Gen Psychiatry (2007) 2.05
Alzheimer's disease neuroimaging initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition. Neuroimage (2009) 2.03
Multivariate deformation-based analysis of brain atrophy to predict Alzheimer's disease in mild cognitive impairment. Neuroimage (2007) 2.03
Measurement of basal forebrain atrophy in Alzheimer's disease using MRI. Brain (2005) 2.03
Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Exp Neurol (2003) 1.99
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry (2005) 1.98
Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement (2013) 1.98
Maternally derived microduplications at 15q11-q13: implication of imprinted genes in psychotic illness. Am J Psychiatry (2011) 1.94
Intensity non-uniformity correction using N3 on 3-T scanners with multichannel phased array coils. Neuroimage (2007) 1.93
Brain fuel metabolism, aging, and Alzheimer's disease. Nutrition (2010) 1.89
Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain. Physiol Genomics (2006) 1.88
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
Integration of fMRI and simultaneous EEG: towards a comprehensive understanding of localization and time-course of brain activity in target detection. Neuroimage (2004) 1.84
Prefrontal transcranial direct current stimulation changes connectivity of resting-state networks during fMRI. J Neurosci (2011) 1.81
Posterior cingulate glucose metabolism, hippocampal glucose metabolism, and hippocampal volume in cognitively normal, late-middle-aged persons at 3 levels of genetic risk for Alzheimer disease. JAMA Neurol (2013) 1.75
Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch Neurol (2005) 1.75
Genomewide association analysis followed by a replication study implicates a novel candidate gene for neuroticism. Arch Gen Psychiatry (2008) 1.75
Factor structure and external validity of the PANSS revisited. Schizophr Res (2005) 1.74
Grey matter correlates of clinical variables in amyotrophic lateral sclerosis (ALS): a neuroimaging study of ALS motor phenotype heterogeneity and cortical focality. J Neurol Neurosurg Psychiatry (2012) 1.70
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry (2012) 1.69
Mapping Alzheimer's disease progression in 1309 MRI scans: power estimates for different inter-scan intervals. Neuroimage (2010) 1.69
Correlations between apolipoprotein E epsilon4 gene dose and whole brain atrophy rates. Am J Psychiatry (2007) 1.68
Adolescent behavior and dopamine availability are uniquely sensitive to dietary omega-3 fatty acid deficiency. Biol Psychiatry (2013) 1.67
The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania. World J Biol Psychiatry (2003) 1.66
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry (2002) 1.63
White matter damage in Alzheimer disease and mild cognitive impairment: assessment with diffusion-tensor MR imaging and parallel imaging techniques. Radiology (2007) 1.61
Depression-related variation in brain morphology over 3 years: effects of stress? Arch Gen Psychiatry (2008) 1.61
Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment. Arch Neurol (2007) 1.61
The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry (2010) 1.61
Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimers Dement (2011) 1.59
A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities. Biol Psychiatry (2006) 1.57
Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease. Neurobiol Aging (2011) 1.57
IFATS collection: The conditioned media of adipose stromal cells protect against hypoxia-ischemia-induced brain damage in neonatal rats. Stem Cells (2009) 1.57
Comparing 3 T and 1.5 T MRI for tracking Alzheimer's disease progression with tensor-based morphometry. Hum Brain Mapp (2010) 1.55
Larger amygdala volumes in first depressive episode as compared to recurrent major depression and healthy control subjects. Biol Psychiatry (2003) 1.55
Automated detection of brain atrophy patterns based on MRI for the prediction of Alzheimer's disease. Neuroimage (2009) 1.55
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry (2012) 1.55
Characterizing Alzheimer's disease using a hypometabolic convergence index. Neuroimage (2011) 1.54
Is aspirin useful in patients on lithium? A pharmacoepidemiological study related to bipolar disorder. Prostaglandins Leukot Essent Fatty Acids (2009) 1.54
A preliminary fluorodeoxyglucose positron emission tomography study in healthy adults reporting dream-enactment behavior. Sleep (2006) 1.54
Child neurology: hemiconvulsion-hemiplegia-epilepsy syndrome. Neurology (2012) 1.54
One generation of n-3 polyunsaturated fatty acid deprivation increases depression and aggression test scores in rats. J Lipid Res (2005) 1.54
Effect of hippocampal and amygdala volumes on clinical outcomes in major depression: a 3-year prospective magnetic resonance imaging study. J Psychiatry Neurosci (2008) 1.53
Multivariate network analysis of fiber tract integrity in Alzheimer's disease. Neuroimage (2006) 1.52
Response and remission criteria in major depression--a validation of current practice. J Psychiatr Res (2010) 1.52
Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends Neurosci (2011) 1.51
Syndromes and phenomenological subtypes underlying acute mania: a factor analytic study of 576 manic patients. Am J Psychiatry (2002) 1.51
The alternative splicing of tau exon 10 and its regulatory proteins CLK2 and TRA2-BETA1 changes in sporadic Alzheimer's disease. J Neurochem (2005) 1.51
Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract (2012) 1.49
Dietary n-3 PUFA deprivation for 15 weeks upregulates elongase and desaturase expression in rat liver but not brain. J Lipid Res (2007) 1.48
The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry (2013) 1.48
Hippocampal and amygdala changes in patients with major depressive disorder and healthy controls during a 1-year follow-up. J Clin Psychiatry (2004) 1.48
Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomark Med (2012) 1.48
Psychosis susceptibility gene ZNF804A and cognitive performance in schizophrenia. Arch Gen Psychiatry (2010) 1.46